Stereotactic body radiotherapy for early-stage non-small cell lung cancer has low post-treatment mortality

Joshua R. Niska,Terence T. Sio,Thomas B. Daniels,Staci Beamer,Dawn E. Jaroszewski,Helen J. Ross,Harshita Paripati,Steven E. Schild

JOURNAL OF THORACIC DISEASE（2018）

引用 1|浏览19

暂无评分

摘要

Stereotactic body radiotherapy (SBRT) is increasingly used to treat stage I non-small cell lung cancer (NSCLC). In 2004, less than 0.5% of these cases were managed with SBRT. By 2011, SBRT accounted for 8.7% of cases (1).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要